Comparing access to orphan medicinal products in Europe

Table 4 Comparison of months elapsed between EC authorisation and reimbursement/publication of HTA recommendation

	Minimum	Maximum	Median	Mean
France	−73.6^a	76.2	17.5	19.5
Italy	−3.0^a	92.0	14.5	18.6
Spain	4.5	51.1	17.4	23.0
England	5.1	53.2	26.8	27.6
Scotland	3.6	64.6	18.8	22.6
Wales	3.6	93.1	26.2	29.3

Source: Authors’ elaboration from data listed in references and time-to access indicator defined in Table 1.
^aThree OMPs were reimbursed in France before EC authorisation: carglumic acid (73.6 months), ataluren (1.3 month), temsirolimus (18 months). One OMP was reimbursed in Italy before EC authorisation: susoctocog alfa (3 months).

ISSN: 1750-1172